Additional file 1: of Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Mahadevan, Daruka; Lanasa, Mark; Farber, Charles; Pandey, Manjari; Whelden, Maria; Faas, Susan; Ulery, Terrie; Kukreja, Anjli; Li, Lan; Bedrosian, Camille; Zhang, Xiaoping; Heffner, Leonard

doi:10.6084/m9.figshare.9728912.v1

40425_2019_710_MOESM1_ESM.docx (829.21 kB)

Additional file 1: of Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

journal contribution

posted on 2019-08-24, 03:54 authored by Daruka Mahadevan, Mark Lanasa, Charles Farber, Manjari Pandey, Maria Whelden, Susan Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille Bedrosian, Xiaoping Zhang, Leonard Heffner

Supplemental data on the Phase I Samalizumab trial of CLL and MM. (DOCX 799 kb)

History

Usage metrics

Keywords

CLL Multiple myeloma CD200 Immune checkpoint inhibitor Samalizumab

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1: of Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

History

Usage metrics

Categories

Keywords

Licence

Exports